CytoSorbents shared its third-quarter results for 2026, showing better sales and smaller losses than last year.

Nov 12, 2026, 4:35 PM ETResultsRead the original at SEC EDGAR

Good for CTSO

CytoSorbents cut costs, sharply narrowed its quarterly loss, and reached slightly positive operating cash flow before restructuring payments. Sales rose only 3%, cash was $5.7 million, and a currency loss widened the nine-month loss, but the quarter's gains support a favorable reading.

CTSO · CytoSorbents Corporation

AI read · Good for CTSO

The AI's read

The company is using less cash to run its business, which eases pressure to seek more money soon. It has not yet returned to profitable growth. Sales rose, but the company still reported a loss. Cash, cash equivalents, and restricted cash fell from $5.9 million in June to $5.7 million. The nine-month net loss grew mainly because of a currency loss that did not use cash. These facts temper, but do not erase, the quarter's cost and cash-flow progress.

Get alerts for CTSO

Follow CytoSorbents Corporation (CTSO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CTSO

Free on the App Store and Google Play, or on the web.